Global Medical Excellence Cluster (GMEC) Appoints Sir Keith Peters as CEO

LONDON--()--GMEC, the largest Global Medical Excellence Cluster in Europe, is delighted to announce the appointment of Sir Keith Peters as its Chairman. Sir Keith brings a wealth of experience and global reputation in medical science to the role. He shares the belief in the opportunity that GMEC can build on its successful first year of operation to enable medical research and patient care to compete at a global level by fostering collaboration between the leading UK universities, hospitals and companies. Sir Keith Peters began his appointment on October 1st.

About GMEC

GMEC brings together in a collaborative effort, leading universities, pharmaceutical and medical device companies and hospitals to build the capabilities which will ensure the UK remains globally competitive in medical research. This will result in improved innovation and product development, more productive leading edge research activity, new employment opportunities and enhanced patient outcomes.

Since its launch, GMEC has widened beyond the founding institutions and encompasses leading universities, pharmaceutical and medical device companies and hospitals. Members include:

  • Universities: Imperial College, King’s College, Oxford University Medical Science Division, School of Clinical Medicine Cambridge University, University College London, and London School of Hygiene and Tropical Medicine;
  • Commercial Sector: GSK, Pfizer and GE Healthcare;
  • Hospitals: South London and Maudsley NHS Foundation Trust and The Royal Marsden NHS Hospital Trust;
  • The London Development Agency.

About Sir Keith Peters

Keith Peters Emeritus Regius Professor of Physic at the University of Cambridge was head of the Cambridge School of Clinical Medicine from 1987-2005. He is a Fellow of the Royal Society and immediate past president of the Academy of Medical Sciences. He was knighted for his services to medicine in 1993. His research has addressed immune mechanisms in kidney and vascular disease; and more generally his interests centre on the application of biomedical science to human disease - the field of translational medicine.

For the past two years he has been Interim Director of the MRC National Institute for Medical Research at Mill Hill, London. He has broad experience of health-related industries having been chair of the Scientific Advisory Board of Amersham Plc (and sometime non-executive director), a member of the Medical Advisory Board of Merck Research Laboratories and as an advisor to various biotechnology companies including Celltech, Cantab Pharmaceuticals and Cambridge Antibody Technology. Sir Keith is currently a senior consultant in R&D to GlaxoSmithKline, and he is a member of the UK Governments Council for Science and Technology.

Contacts

Mike Standing
Mike_Standing@Monitor.com
or
Monitor Group
Hanno Ronte
Tel: 020 78386500
Hanno_Ronte@monitor.com
or
www.GMECuk.co.uk

Contacts

Mike Standing
Mike_Standing@Monitor.com
or
Monitor Group
Hanno Ronte
Tel: 020 78386500
Hanno_Ronte@monitor.com
or
www.GMECuk.co.uk